--- title: "GLP-1 Drugs and the Lateral Septum: The Brain Circuit Behind Reduced Cravings" slug: glp1-lateral-septum-reward-circuit-2026 category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-08-13 tags: ["GLP-1", "lateral septum", "neuroscience", "alcohol use disorder", "semaglutide", "liraglutide", "dopamine", "addiction research"] read_time_minutes: 11 canonical_url: https://brainwavepost.com/article/glp1-lateral-septum-reward-circuit-2026 source: BrainWavePost --- # GLP-1 Drugs and the Lateral Septum: The Brain Circuit Behind Reduced Cravings *Health · 2026-08-13 · BrainWavePost Staff · 11 min read* > A 2026 Neuron study mapped a specific inhibitory circuit in the lateral septum that carries GLP-1's effect on alcohol reward in mice. Here is what the experiments actually showed, how it fits the human trial data, and where the popular 'Ozempic kills all cravings' story runs ahead of the evidence. > **This is health journalism, not medical advice** _(note)_ > > Nothing here is a treatment recommendation. GLP-1 receptor agonists are not approved anywhere for alcohol, nicotine or any other substance use disorder, and the central study described below was done in mice. Decisions about medication belong with your own clinician. [1][2][6] The story that GLP-1 medications quiet cravings for things other than food has been circulating for years, mostly as anecdote: people on semaglutide or liraglutide reporting that alcohol lost its pull, or that cigarettes stopped appealing. What was missing was a mechanism — a specific place in the brain where a metabolic drug could reach into reward processing. A study published in Neuron in 2026 offers one, and it points at the lateral septum. [1][2] Led by Yingjie Zhu and Zijun Chen at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, the work is titled “A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.” The title is deliberately narrow, and the narrowness matters. [1][2] - **Neuron, 2026** — peer-reviewed primary source for the septal circuit finding [1] - **Mice** — the species in which the circuit was mapped and manipulated [1] - **n = 48** — participants in the phase 2 semaglutide alcohol trial in humans [6] ## Why the lateral septum is a plausible hub The lateral septum sits between the forebrain and the limbic system and is unusually dense in GLP-1 receptors, while also being wired into reward-related behaviour. That combination is what made it a candidate: a region where a circulating metabolic signal could plausibly modulate motivation rather than only appetite. Earlier rodent work in eBioMedicine had already shown that activating GLP-1 receptors in the lateral septum attenuated alcohol's rewarding effects, reduced alcohol-induced dopamine release in the nucleus accumbens, and cut alcohol intake without changing food or water consumption — while blocking those receptors pushed alcohol intake up. [3] The 2026 Neuron paper takes that regional observation and resolves it into a circuit. [1][3] ## What the experiments showed - Systemic liraglutide reduced alcohol intake and reduced ethanol-evoked dopamine release in the nucleus accumbens — and that effect required GLP-1 receptor expression in the dorsal lateral septum (dLS). Remove the receptors there, and the drug's effect on drinking went with them. [1] - Alcohol consumption suppressed the activity of dLS GLP-1R neurons. Liraglutide prevented that alcohol-induced suppression of calcium dynamics, i.e. it kept the brake engaged. [1] - Inactivating dLS GLP-1R neurons increased alcohol consumption and abolished liraglutide's behavioural effect; chemogenetically activating them suppressed alcohol-directed behaviour. Both directions of the manipulation behaved as the model predicts. [1] - Circuit tracing found a local inhibitory projection from dLS GLP-1R neurons onto estrogen-receptor-1-expressing neurons in the ventral lateral septum (vLS Esr1 neurons). Inhibiting those vLS neurons mimicked liraglutide's effect — and occluded it, meaning the drug had nothing left to add. [1][2] > **Why 'occlusion' is the strongest sentence in the paper** _(info)_ > > If manipulating a circuit directly reproduces a drug's effect and then leaves the drug with no additional effect, that is much stronger evidence that the drug works through that circuit than a mere correlation of activity. This is the experimental logic that separates the Neuron result from the earlier observational picture. [1] ## The dampening story, stated precisely The popular framing — a metabolic drug reaching into the reward system and turning the volume down — is broadly right in shape. The precise version is that GLP-1 receptor signalling in the dorsal lateral septum sustains an inhibitory microcircuit that constrains alcohol reward, with the downstream readout being reduced alcohol-evoked dopamine release in the nucleus accumbens. Alcohol itself tends to switch that brake off; the drug stops it from being switched off. [1][2] > GLP-1R neurons in the dLS directly inhibited neurons expressing estrogen receptor 1 (Esr1) in the vLS, and targeted manipulation of this circuit confirmed its role in regulating alcohol intake. > > — Zhu and Chen et al., Neuron (2026), as summarised in the SIAT research announcement [1][2] ## Where nicotine actually comes into it This is the point where careful reading matters most. The Neuron study is about alcohol. It did not test nicotine, and it does not establish a shared septal mechanism for tobacco craving. [1] The human hint about nicotine comes from somewhere else: a phase 2, double-blind randomised trial of once-weekly low-dose semaglutide in 48 non-treatment-seeking adults with alcohol use disorder, published in JAMA Psychiatry in February 2025. Alongside its alcohol findings, a preplanned secondary analysis restricted to the 13 participants who smoked at baseline found that semaglutide predicted greater relative reductions in cigarettes per day. Thirteen people is a signal worth following, not a conclusion. [6][7] A 2026 systematic review in Frontiers in Pharmacology surveys the wider evidence base for GLP-1 receptor agonists across substance use disorders, and the honest summary of that literature is that preclinical results are consistent and human results are early and mixed. [4] ## What the human trial found on alcohol - Over 9 weeks, low-dose semaglutide reduced the amount of alcohol consumed in a laboratory self-administration task, with medium-to-large effect sizes for grams consumed and peak breath alcohol concentration. [6] - It significantly reduced drinks per drinking day and weekly alcohol craving, and predicted greater reductions in heavy drinking over time relative to placebo. [6] - It did not affect average drinks per calendar day or the number of drinking days — so 'drinks less when drinking' rather than 'drinks on fewer days'. [6] - The authors' own conclusion is that the findings justify larger trials, not that a treatment has been established. [6][7] ## How far the mouse result travels - Species. The circuit was mapped in mice, using chemogenetics and viral receptor deletion — tools that do not exist for human patients. Circuit homology between mouse and human septum is assumed, not demonstrated here. [1] - Drug. Liraglutide was the agonist in the septal study; the human alcohol trial used semaglutide. Different molecules with different brain penetrance and dosing schedules. [1][6] - Behaviour. Alcohol intake and place preference in a cage are not the same construct as compulsive human drinking with social and psychiatric context. [1][4] - Sex. The earlier eBioMedicine work found lateral-septum GLP-1R expression correlated with alcohol intake in male but not female rats, suggesting sex-specific effects after long-term exposure. Any single-mechanism story should be held loosely. [3] - Scope. Appetite suppression, alcohol reward and nicotine use are being folded into one narrative by headlines faster than by data. The septal circuit is evidence for one of the three. [1][4] ## What is still unknown - Whether the same dLS-to-vLS inhibitory circuit carries GLP-1 effects on non-alcohol rewards such as nicotine, stimulants or gambling-like behaviour. Not tested in this study. [1] - Whether the circuit is engaged at the doses people actually take for weight or glycaemic control, versus doses used experimentally in rodents. [1][6] - Whether craving reduction persists after the medication stops, or rebounds along with appetite. [4][6] - Whether any of this becomes a treatment. No GLP-1 receptor agonist is approved for alcohol or nicotine dependence, and regulators have licensed these drugs for metabolic indications. [5][6] > **If this describes you** _(tip)_ > > If you are on a GLP-1 medication and notice changes in drinking, smoking or other cravings, that is worth telling your prescriber — both because it is clinically interesting and because unmanaged withdrawal from alcohol can be dangerous. If you are considering these drugs because of cravings rather than metabolic indications, that is a conversation for a clinician, not a decision to make from a research summary. Support services for alcohol and tobacco exist independently of any of this. [5][6] ## Sources and further reading - [1] Neuron (Cell Press) — Chen, Zhu et al., 'A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice' (2026): https://www.cell.com/neuron/abstract/S0896-6273(26)00125-X - [2] Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences — 'How Weight-loss Medication Dampens Down Alcohol Intake: Researchers Pinpoint Key Septal Brake' (23 March 2026): https://english.siat.ac.cn/news/sr/202603/t20260323_1153166.html - [3] eBioMedicine (The Lancet Discovery Science) — 'An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents' (2025), open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC12044336/ - [4] Frontiers in Pharmacology — 'The potential role of GLP-1 receptor agonists in substance use disorders: a systematic review' (2 January 2026): https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1702448/full - [5] National Institute on Alcohol Abuse and Alcoholism (NIH) — treatment overview and approved medications for alcohol use disorder: https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics - [6] JAMA Psychiatry — Hendershot et al., 'Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial' (12 February 2025), full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/ - [7] Reuters — 'Ozempic shows some promise for alcohol use disorder' (12 February 2025): https://www.reuters.com/business/healthcare-pharmaceuticals/ozempic-shows-some-promise-alcohol-use-disorder-2025-02-12/ - [8] ClinicalTrials.gov — NCT05520775, the registration record for the semaglutide alcohol use disorder trial: https://clinicaltrials.gov/study/NCT05520775 --- _Canonical article: [https://brainwavepost.com/article/glp1-lateral-septum-reward-circuit-2026](https://brainwavepost.com/article/glp1-lateral-septum-reward-circuit-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._